9/12/2022 8:08:01 AM
Regulus Announces Positive Safety And Pharmacokinetic Data From Phase 1 Trial Of RGLS8429 For Treatment Of ADPKD
6/21/2022 8:08:52 AM
Regulus Therapeutics Gets FDA Orphan Drug Designation For RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
6/13/2022 8:21:48 AM
Regulus :First Subject Dosed In Phase 1 Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease Treatment
5/11/2022 8:06:09 AM
Regulus : FDA Accepts IND Application For RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease
3/24/2022 8:03:49 AM
Regulus Initiates Preclinical Studies In Amyotrophic Lateral Sclerosis Under Agreement With Harvard's Brigham
2/24/2022 8:11:01 AM
Regulus Therapeutics Completes Enrollment In Phase 2 Clinical Trial Of Lademirsen For Alport Syndrome
12/3/2021 8:31:58 AM
Regulus Appoints Mohammad Ahmadian As VP Chemistry And Pharmaceutical Development
6/25/2021 7:06:41 AM
Regulus Therapeutics Presents Addl Data From ADPKD Program At PKD Connect 2021
5/21/2021 8:10:44 AM
Regulus Therapeutics Report Incremental Update From First Cohort Of Patients With ADPKD In RGLS4326 Phase 1b Trial
5/3/2021 8:16:15 AM
Regulus Therapeutics Announces Top-Line Data From First Cohort Of Phase 1b Clinical Trial Of RGLS4326
4/15/2021 8:31:05 AM
Regulus Therapeutics Completes Dosing In First Cohort Of Phase 1b Trial Of RGLS4326 For ADPKD
3/9/2021 4:08:34 PM
Regulus Therapeutics Q4 Loss/share $0.03 Vs. Loss $0.23 Year Ago
2/10/2021 8:11:24 AM
Regulus Completes Enrollment In First Cohort Of Phase 1b Trial Of RGLS4326 For Treatment Of Patients With ADPKD
1/27/2021 8:08:19 AM
Regulus Therapeutics Names Alice Huang To Board Of Directors